BACKGROUND: Although oxytocin commonly is used to augment or induce labor, it is difficult to predict its effectiveness because oxytocin dose requirements vary significantly among women. One possibility is that women requiring high or low doses of oxytocin have variations in the oxytocin receptor gene. OBJECTIVES: To identify oxytocin receptor gene variants in laboring women with low and high oxytocin dosage requirements. STUDY DESIGN: Term, nulliparous women requiring oxytocin doses of 4 mU/min (low-dose-requiring, n ¼ 83) or !20 mU/min (high-doserequiring, n ¼ 104) for labor augmentation or induction provided consent to a postpartum blood draw as a source of genomic DNA. Targetedamplicon sequencing (coverage >30Â) with MiSeq (Illumina) was performed to discover variants in the coding exons of the oxytocin receptor gene. Baseline relevant clinical history, outcomes, demographics, and oxytocin receptor gene sequence variants and their allele frequencies were compared between low-dose-requiring and high-dose-requiring women. The Scale-Invariant Feature Transform algorithm was used to predict the effect of variants on oxytocin receptor function. The Fisher exact or c 2 tests were used for categorical variables, and Student t tests or Wilcoxon rank sum tests were used for continuous variables. A P value < .05 was considered statistically significant. RESULTS: The high-dose-requiring women had greater rates of obesity and diabetes and were more likely to have undergone labor induction and required prostaglandins. High-dose-requiring women were more likely to undergo cesarean delivery for first-stage arrest and less likely to undergo cesarean delivery for nonreassuring fetal status. Targeted sequencing of the oxytocin receptor gene in the total cohort (n ¼ 187) revealed 30 distinct coding variants: 17 nonsynonymous, 11 synonymous, and 2 small structural variants. One novel variant (A243T) was found in both the low-and high-dose-requiring groups. Three novel variants (Y106H, A240_A249del, and P197delfs*206) resulting in an amino acid substitution, loss of 9 amino acids, and a frameshift stop mutation, respectively, were identified only in lowdose-requiring women. Nine nonsynonymous variants were unique to the high-dose-requiring group. These included 3 known variants (R151C, G221S, and W228C) and 6 novel variants (M133V, R150L, H173R, A248V, G253R, and I266V). Of these, R150L, R151C, and H173R were predicted by Scale-Invariant Feature Transform algorithm to damage oxytocin receptor function. There was no statistically significant association between the numbers of synonymous and nonsynonymous substitutions in the patient groups. CONCLUSION: Obesity, diabetes, and labor induction were associated with the requirement for high doses of oxytocin. We did not identify significant differences in the prevalence of oxytocin receptor variants between low-dose-requiring and high-dose-requiring women, but novel oxytocin receptor variants were enriched in the high-dose-requiring women. We also found 3 oxytocin receptor variants (2 novel, 1 known) that were predicted to damage oxytocin receptor function and would likely increase an individual's risk for requiring a high oxytocin dose. Further investigation of oxytocin receptor variants and their effects on protein function will inform precision medicine in pregnant women.
Introduction
Oxytocin commonly is used to induce or augment labor and is one of the most frequently used medications in obstetrics. This nonapeptide hormone, which is secreted by the pituitary gland, corpus luteum, placenta, amnion, and decidua, acts on uterine smooth muscle to initiate, enhance, and pace uterine contractions. [1] [2] [3] On average, nearly one half of women who give birth in the United States are administered synthetic oxytocin to induce or augment labor. 4, 5 However, the effectiveness of a given oxytocin dose varies among women; consequently, oxytocin has a relatively wide therapeutic window, between 1 mU/min and greater than 40 mU/min.
Frey et al 6 recently identified several risk factors for requiring high doses of oxytocin, including diabetes, intrapartum fever, and large fetal birthweight. However, many women with these risk factors only require low doses of oxytocin, and those without any risk factors may require high doses of oxytocin, indicating an incomplete understanding of the etiologies of high oxytocin dose requirement. The unpredictability of an individual patient's sensitivity to exogenous oxytocin and subsequent prolonged oxytocin exposure increases the risks of uterine rupture, hemorrhage, hyponatremia, tachysystole, and fetal hypoxia, acidemia, and abnormal heart rate tracings. 7 Furthermore, the variability of responsiveness to oxytocin may contribute to the increasing national cesarean delivery rate for the indication of labor dystocia.
Oxytocin induces uterine contractility by binding to the oxytocin receptor (OXTR), a G-proteinecoupled receptor. Binding initiates a signaling cascade that results in an increased intracellular calcium concentration and activation of the contractile machinery. To successfully OXTR variants have been associated with neurologic disorders including autism spectrum disorders and schizophrenia. [8] [9] [10] [11] [12] However, many variants identified in these studies were in noncoding regions surrounding the gene, and effects on function are unknown. Kim et al 13 investigated the link between OXTR variants and preterm birth but did not find any variants that were statistically associated with preterm birth. The objective of our study was to identify OXTR variants in women requiring low or high doses of oxytocin during labor induction or augmentation.
Materials and Methods

Study cohort and inclusion and exclusion criteria
This prospective study included nulliparous women at or beyond 37 weeks of gestation with singleton, nonanomalous pregnancies who received oxytocin for labor or induction of labor at a tertiary care medical center between September 2013 and May 2016. Institutional review board approval was obtained from the Washington University School of Medicine Human Research Protection Office (IRB 201108143, approved Sept. 22, 2011) . Exclusion criteria included a history of HIV or hepatitis, multiple pregnancies, age <13 or >48 years old, or the receipt of magnesium. Patients meeting inclusion criteria were enrolled and consented postpartum by trained research nurses.
Group assignments
The low-dose-requiring (LDR) women were defined as those who received a maximum dose of 4 mU/min oxytocin, and high-dose-requiring (HDR) women were those who received !20 mU/min oxytocin. These groups were selected because they fell below the 25th percentile and above the 95th percentile of oxytocin dose within our population of laboring patients. 6 Our institutional protocol for oxytocin administration allows for either highdose or low-dose regimens at the discretion of the obstetric provider. The low-dose regimen starts at an initial rate of 2 mU/min with an increase of 2 mU/min every 20 minutes to a maximum of 40 mU/min. The highdose regimen starts at 6 mU/min with an increase of 6 mU/min every 20 minutes to a maximum of 40 mU/min. The LDR group exclusively included women on the low-dose regimen, and the HDR group included women on either the high-or low-dose regimens. Trained research nurses reviewed medical charts to extract pertinent clinical history, outcomes, and demographics.
DNA extraction
Women who provided consent underwent a postpartum blood draw, and genomic DNA was extracted from blood samples by a salting-out procedure described by Miller et al, 14 or with Table) were added to the assay inlets at 200 nM each in 1Â Access Array Loading Reagent. Multiplex PCR amplification was ajog.org
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performed on the Fluidigm BioMark HD system with each patient sample, which also was tagged with a 10-base pair index. Samples were pooled and beadpurified before sequencing (250-bp paired-end read length, MiSeq; Illumina, Inc, San Diego, CA).
Variant identification and filtering
Sequence data were analyzed with a custom pipeline. Raw sequence reads were trimmed to remove primer sequences and aligned to human reference sequence hg19 with NovoAlign v2.08.02 (Selangor, Malaysia). Variants were called with FreeBayes v0.9.7 15 and then filtered with SnpSift for quality scores of 1000 or greater, depth of 40 or more reads, and percent of paired reads !20%. Variants were annotated with SnpEff. 16, 17 Each variant call was supported by an average of 16,800 reads, and only reads with mapping quality !30 were considered for analysis. For each variant identified in individual patients, base call quality was determined as the negative log-probability that a base had not been sequenced correctly. Mapping quality per identified variant was defined as the negative log-probability that a read mapped to a unique location in the OXTR reference sequence.
Variants were excluded from the study if <10 reads supported the alternate allele, <20% of the reads supported the alternate allele, and if <10 reads mapped to a site in the OXTR gene. Variants with a base call quality <20, a mapping quality <30, and a base call quality þ mapping quality <40 also were excluded from the analysis. Variants were named according to the Human Genome Variation Society's guidelines for genetic and protein variant nomenclature.
18 SnpEff v3.3c was used to determine amino acid changes, and the Variant Effect Predictor was used to determine SIFT scores. 19 
Statistical analyses
Baseline characteristics were compared between LDR and HDR groups and were statistically assessed by the Fisher exact or c 2 tests for categorical variables and Student t tests or Wilcoxon rank sum test for continuous variables. A P value < .05 was considered significant. Homozygous variants were assigned an allele count of 2, and heterozygous variants were assigned an allele count of 1. Homozygous variants that matched the reference allele were assigned an allele count of 0. Allele frequencies were calculated as the sum of alleles divided by the total number of possible alleles in the patient cohort (number of patients Â 2). Odds ratios, probabilities, and confidence intervals were calculated as described in Szumilas 20 with variant type (synonymous or nonsynonymous) as the exposure variable.
Results
Targeted sequencing of the OXTR gene was performed on DNA obtained from women providing consent who were treated with oxytocin for labor induction or augmentation (Figure 1) . Of 187 women, 104 (56%) were defined as HDR, and 83 (44%) were LDR. One LDR sample failed to yield quality sequence data and was eliminated from any further analysis.
Compared with those in the LDR group, women in the HDR group were more likely to be obese, have diabetes, undergo induction of labor, and require prostaglandins for induction (Table 1) . There was no difference in age, race, gestational age, or indication for induction between groups. After we adjusted for confounders, HDR was associated with an increased risk of cesarean delivery for first-stage arrest (adjusted odds ratio, 5.4; 95% confidence, 1.8 to 16.7) and a decreased risk of cesarean delivery for nonreassuring fetal status (adjusted odds ratio, 0.3; 95% confidence interval, 0.1 to 0.8). There were no differences in rates of vaginal delivery, cesarean delivery, or completion of first stage of labor between the 2 groups ( Table 2) .
We identified 30 OXTR variants, of which 17 were nonsynonymous substitutions (NSS), 11 were synonymous substitutions (SS), and two were small structural variations (Table 3) . Moreover, 10 variants were novel (ie, not identified in Ensembl, ExAC, or the literature). [21] [22] [23] Of these, 8 were NSS (Y106H, R150L, M133V, H173R, A243T, A248V, G253R, and I266V), and 2 were deletions (A240_A249del and P197delfs*206).
Because NSS variants were more likely to affect the structure and function of OXTR than SS variants, we sought to determine whether the women in the HDR group had a greater burden of NSS OXTR variants than the women in the LDR group. We identified 14 NSS and 6 SS variants in women in the HDR group 8 NSS and 7 SS in women in the LDR group (Table 3 and data not shown). Twelve NSS variants were each identified in only 1 individual (either HDR or LDR, minor allele frequency <1%; Table 3 ). Relative risk assessment determined that women in the HDR group were 1.31 (0.78 to 2.44) times more likely than women in the LDR group to have a NSS, but this difference was not statistically significant (P ¼ .48). Both groups had a greater representation of SS variants than NSS variants (mean 59.6% vs 33.2%). A greater percentage of women in the HDR group than the LDR group had NSS alleles (34.6% vs 31.7%), but this difference was not statistically significant (P ¼ .68). These data show no significant difference between overall OXTR variant load in oxytocin women in the HDR vs LDR group.
To determine whether variants were likely to affect the structure and function of the OXTR protein, we used the SIFT algorithm, which classifies variants as "Damaging," "Tolerated," or "No Prediction" based on evolutionary conservation and the biochemical properties of the substituted amino acid. 24 SIFT classified 4 of the 17 nonsynonymous OXTR single-nucleotide variants (SNVs) as "Damaging" (R150L, R151C, H173R, W195R), including 3 SNVs in the HDR group (R150L, R151C, H173R) ( Table 3) . Two of these, R150L and H173R, were novel. SIFT classified the remaining 13 SNVs as "Tolerated." We also identified 2 novel deletions in OXTR: a 27-bp deletion and a frameshift deletion (A240_A249del and P197Pdelfs*206) that are anticipated to result in a 9 amino acid deletion and a frameshift stop-gain mutation, respectively.
Comment
Our study identified 10 novel variants of OXTR, and 6 of these were unique to women requiring high doses of oxytocin. Both women in the HDR and LDR groups had more NSS variants than SS variants of OXTR, and women in the HDR group had more potentially damaging variants. Although these findings were not statistically significant, they suggest a genetic component to oxytocin sensitivity in women undergoing labor induction or augmentation.
Four of the NSS variants were predicted by SIFT to be damaging (R150L, R151C, H173R, and W195R). A variant in R150, R150S, was identified previously in an individual with autism spectrum disorder. 25 This residue is part of the OXTR "polar pocket," which changes conformation during receptor activation and is involved in G-protein interaction. [26] [27] [28] R151C was annotated previously in the Ensembl database (rs772841181), but its functional impact is not known. Given its polarity and proximity to R150, R151 may contribute to the stability of the polar pocket. H173 and W195 are located within the regions of the OXTR binding pocket that recognize the cyclic and linear, respectively, components of oxytocin. 26, 29 The ajog.org
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cyclic binding region is thought to confer more specificity for oxytocin binding than the region recognizing the linear portion of oxytocin, so the H173R and W195R mutations may differentially disrupt oxytocin binding strength or specificity. The other OXTR variants we identified in women in the HDR group, G221S, W228C, V172A, L206V, A218T, and A238T, were all in the Ensembl and ExAC databases (see Table 3 ), but their phenotypic effects are unknown. Neither these nor the other 9 OXTR variants we found were predicted by SIFT to be damaging, but this does not preclude them from having unpredictable damaging effects on OXTR function. Future in vitro studies should reveal the effects of these variants on OXTR function.
Previously, Kim et al 13 investigated the link between OXTR variants and preterm birth but did not find any variants that were associated statistically with preterm birth. Kim et al 13 identified some novel and damaging variants, including the more common variants in our study (V172A, L206V, A218T, and A238T), but we note no overlap in our studies between the extremely lowfrequency (0.003) variants we found or the predicted damaging variants they found. By using a heterologous expression system, Kim et al 13 showed that some of their variants reduced oxytocin binding and inositol trisphosphate production capability. Taken together, our studies suggest that oxytocin sensitivity is, at least in part, genetically determined.
A strength of our study is our use of high-throughput targeted amplicon sequencing, which enabled us to discover and individually genotype the variants across the entire patient cohort. In contrast, several previous studies in search of genetic variation in disease and patient outcomes have relied on SNP microarrays and subsequent Sanger sequencing for validation. Another advantage of our study is that we were able to estimate the effects of the variants we identified by using software that has proven useful in predicting the molecular effects of variants in other genes. 30, 31 Our study has some potential limitations to consider. By only sequencing exons, we may have missed variants in the promoter affecting gene Variants that were not identified in Ensembl and ExAC are indicated with an asterisk (*) and their genomic position in hg19. For the nucleotide substitutions underlying each of the amino acid substitutions, major and minor alleles are shown on the left and the right of the carat, respectively.
HDR, high-dose-requiring; IC, intracellular; LDR, low-dose-requiring; OT, oxytocin; OXTR, oxytocin receptor protein; TM, transmembrane domain. Original Research OBSTETRICS ajog.org expression, enhancers affecting allelespecific expression, or splice acceptor site mutations in introns. Variants in these regions could affect overall OXTR expression levels, which also could have a profound effect on oxytocin responsiveness, as myometrial OXTR levels increase in preparation for labor. 32, 33 In addition, the highly guanine rich region in the 5 0 end of prevented us from designing robust primers for PCR amplification and thus precluded our abilities to successfully sequence this region in any of the samples. We anticipate future high-throughput sequencing strategies to resolve the 5 0 end of OXTR in women of interest, especially those with no other risk factors for decreased oxytocin sensitivity. Although we discovered 14 OXTR variants in HDR women, our study was not powered to investigate whether any of the variants contributed to LDR or HDR status. However, the results provide novel information about unique OXTR variants that have not been previously identified or described.
This study corroborated the findings by Frey et al 6 demonstrating that maternal body mass index (BMI), maternal diabetes, and labor induction were risk factors for requiring high doses of oxytocin to achieve delivery. We found that patients in the HDR group were more likely than patients in the LDR group to have cesarean deliveries for first-stage arrest and less likely to have cesarean deliveries for nonreassuring fetal status. We suspect that those with nonreassuring fetal status were likely to proceed to cesarean delivery sooner, thereby limiting duration of oxytocin exposure and titration. There was no difference in second-stage arrest between women in the HDR and LDR groups, suggesting that the genetic aspect of oxytocin sensitivity is most applicable for first-stage management. The women in the HDR group with NSS variants predicted to be damaging (H173R, R151C, and R150L) had the additional risk factor of labor induction. The subject with the R151C variant also had a high BMI (35.7 kg/m 2 ), and the subject with R150L had a high BMI (45.5 kg/m 2 ), pregestational diabetes, and large birthweight (4125 g). Thus, although these women's requirements for a high dose of oxytocin cannot be attributed to the variants alone, the variants may add additional risk.
This study suggests that a genetic factor, variation in OXTR, is associated with oxytocin responsiveness during labor. Although these results are insufficient to make absolute conclusions about the effect of the OXTR variants we identified on uterine contractions and labor dystocia, they introduce novel genetic variants that will serve as a foundation for future work. Future studies should include a larger sample size of women to assess more fully the association between specific OXTR variants, requirement for high and low oxytocin doses, and labor arrest diagnoses. In addition, functional studies evaluating oxytocin binding, downstream signaling, and myometrial contractility should be performed to assess consequences of the variants we identified. In combination with our study, such experiments will improve our knowledge about genetic contributions to oxytocin responsiveness and may, in the long term, contribute to precision medicine in managing labor. n
